Volume depletion due to persistent glucosuria-induced osmotic diuresis is a significant problem in uncontrolled diabetes mellitus (DM). Angiotensin II receptor blockers (ARBs), such as candesartan, slow the progression of chronic kidney disease in patients with DM. However, mice with genetic knock-out of components of the renin-angiotensin system have urine concentrating defects, suggesting that ARBs may exacerbate the volume depletion. Therefore, the effect of candesartan on UT-A1, UT-A3, NKCC2, and AQP2 protein abundances was determined in control and 3-week DM rats. Aldosterone levels in control rats (0.36±0.06 nM) and candesartan-treated rats (0.34±0.14 nM) were the same. DM rats had higher aldosterone levels (1.48±0.37 nM) that were decreased by candesartan (0.97±0.26 nM). Western analysis showed that UT-A1 expression was increased in DM rats compared to controls in IM tip (158±13%) and base (120±25%). UT-A3 abundance was increased in IM tip (123±11%) and base (146±17%) of DM rats vs. controls. UT-A3 was unchanged in candesartan-treated control rats. In candesartan-treated DM rats, UT-A3 increased in IM tip (160±14%) and base (210±19%). Candesartan-treated DM rats had slightly higher AQP2 in IM (46%, p<0.05) vs control rats. NKCC2/BSC1 was increased 145±10% in outer medulla of DM vs. control rats. We conclude that candesartan augments compensatory changes in medullary transport proteins, reducing the losses of solute and water during uncontrolled DM. These changes may represent a previously unrecognized beneficial effect of type 1 Angiotensin II receptor blockers in diabetes mellitus.